Seeking to remake corporate America, a nonprofit has released a ranking of the largest publicly traded companies in the U.S. It is based on issues that its own polling finds are important to the public, such as worker pay and treatment, customer respect, and product quality, among many other things.

And while drug makers did not rate in the very highest positions, seven of these companies did fall within the Top 100, starting with Eli Lilly (LLY) at number 28. The others are Biogen (BIIB), Bristol-Myers Squibb (BMY), Johnson & Johnson (JNJ), Celgene (CELG), Merck (MRK), and AbbVie (ABBV). All totaled, 1,000 companies were ranked, and 42 drug companies made the list.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy